On April 24, 2023 Dyve Biosciences, Inc. ("Dyve"), a clinical-stage platform biotechnology company with assets in immunology and oncology, reported the summary results of a poster presentation from the on-going preclinical partnership with the H. Lee Moffitt Cancer Center & Research Institute ("Moffitt") showing preclinical data from the company’s unique delivery approach that unlocks the powerful effects of neutralizing the TME acidity (Press release, Dyve Biosciences, APR 24, 2023, View Source [SID1234630415]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster, presented in collaboration with Moffitt, showcased data demonstrating the delivery of intuitive, targeted pH modulation to treat solid tumors. Tumor acidosis plays a major role in tumor aggressiveness, invasion, and resistance and is an important target for novel anticancer strategies. In the presentation, Dyve and Moffitt demonstrated for the first time that the extracellular pH of tumors can be increased upon application of a buffer formulation delivered transdermally, bypassing the GI tract and unlocking a more viable route to TME buffering therapy in oncology.
"Dyve continues to advance research in areas where our pH modulation program can unlock decades of ‘settled science’ using our proprietary delivery technology. Our transdermal alkalinization treatment induced pH changes in a murine melanoma model as measured with MRI-CEST pH imaging and demonstrated for the first time that the extracellular pH of tumors can be increased upon application of a buffer formulation delivered transdermally. We are eager to translate these promising results into the clinic, including through our strategic alliance with Moffitt, and believe the on-going studies will continue to validate our approach and ultimately benefit patients across a number of different tumor types." – Ryan Beal, M.D., CEO, Dyve Biosciences
The research was published in AACR (Free AACR Whitepaper) Journals and is available here: View Source